Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. conclude this 3-part series with discussions on pipeline innovations and adjunctive strategies for treating challenging prosthetic joint infections. Topics include local antibiotic administration, phage therapy, and immunotherapy. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. continue discussing long-acting antibiotics, systemic vs. oral antibiotics, and drug and dosing perspectives in episode 2 of this 3-part conversation. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395 

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Host Jessica Seidelman, MD has an in-depth discussion with Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. in the opening episode of this 3-part series. They discuss why PJI infections are so difficult to treat, and advances in antimicrobial agents in the pipeline. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss another challenging case with Jenny Aronson, MD.  Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a the first of two challenging cases with Jenny Aronson, MD. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Jessica Seidelman, MD, and Johannes Plate, MD. PhD conclude this discussion on the role of the Megaprosthesis in oncological indications with Juan Pretell, MD and Santiago Lozano-Calderon, MD, PhD. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Jessica Seidelman, MD, and Johannes Plate, MD, PhD host Juan Pretell, MD and Santiago Lozano-Calderon, MD, PhD as they discuss the role of the Megaprosthesis in oncological indications. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including results from the APEX clinical trials, please visit Ostealtx.com

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Alaina Ritter, MD, and Minu Abraham, MD. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Jakrapun Pupaibool, MD, MS. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they conclude the discussion, Patient Perspectives of PJI with William Jiranek, MD, and  James Campbell, who is a registered nurse, a vascular access specialist, and a prosthetic joint infection survivor. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here